OptimizeRx Has Quietly Become One of the Russell 2000’s Top Performers Thanks to a Revamped Revenue Model
Some stocks need a doctor — OptimizeRxOPRX is writing its own prescription for success, connecting pharma firms with healthcare providers and patients. The digital health platform has jumped 198% YTD, making it one of the Russell 2000’s standout performers. Unlike many top-performing small caps, which owe their gains to acquisition rumors or one-time data releases, OptimizeRx’s rally stems from solid fundamentals and a strategic business transformation.
- OptimizeRx posted Q1 2025 revenue of $21.9M, representing an 11% year-over-year increase that beat analyst expectations, while gross profit climbed 9% during the same period.
- The company’s shift toward subscription-based contracts is paying dividends, with over 5% of 2025 sales now recurring, and management expects this trend to continue in the coming quarters.
The diagnosis looks promising: OptimizeRx has two main lines of business — one that helps healthcare providers deliver targeted messages through electronic health records and a direct-to-consumer arm expanded through its 2023 acquisition of Medicx. The organization just raised its full-year 2025 revenue outlook to between $101M and $106M, with adjusted EBITDA now expected to come in between $13M and $15M. With over 80% of this year’s revenue already locked in through existing contracts, OptimizeRx appears to have found the right formula for sustained growth in the expanding digital pharma marketing space.